Browsing by Author Haber, Michelle

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 11 of 11
Issue DateTitleAuthor(s)Citation
2006The Estrogen-responsive B Box Protein Is a Novel Regulator of the Retinoid SignalRoediger, Ben; Bell, Jessica; Bohlken, Andrew; Cheung, Belamy B.; Haber, Michelle; Kavallaris, Maria; Lee, Michelle; Liu, Hsiao-Lai; Marshall, Glenn M.; Norris, Murray D.; Poljak, Anne; Raif, Anna; Smith, Stewart; Thomas, Wayne D; Yan, Joanne; Zajchowski, Deborah; Infectious DiseasesThe Estrogen-responsive B Box Protein Is a Novel Regulator of the Retinoid Signal, Journal of Biological Chemistry, vol.181,(26),2006,pp 18246-18256
2005Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitroAllen, John; Tanabe, K; Tobin, Peter; Cohn, Susan L.; Flemming, Claudia L.; Haber, Michelle; London, Wendy B.; Marshall, Glenn M.; Norris, Murray D.; Scheffer, George L.; Smith, Janice; Wielinga, Peter; Central Clinical School: Centenary Institute; Clinical Schools; School of Medical Sciences: PharmacologyExpression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro, Molecular cancer therapeutics, vol.4,(4),2005,pp 547-553
2015Folate pathway gene polymorphisms and risk of childhood brain tumors: Results from an Australian case-control studyArmstrong, Bruce; Ashton, Lesley; Attia, John; Bower, Carol; de Klerk, Nicholas; Gottardo, Nick; Greenop, Kathryn R; Haber, Michelle; Jamieson, Sarra; Milne, Elizabeth; Norris, Murray; Scott, Rodney J; van Bockxmeer, Frank; School of Public Health: Public Health; Research Grants and ContractsFolate pathway gene polymorphisms and risk of childhood brain tumors: Results from an Australian case-control study, Cancer Epidemiology, Biomarkers and Prevention, vol.24, 6, 2015,pp 931-937
2015Folate pathway gene polymorphisms, maternal folic acid use and risk of childhood acute lymphoblastic leukemiaArmstrong, Bruce; Attia, John; Bailey, Helen; Bower, Carol; et al, Various; Greenop, Kathryn R; Haber, Michelle; Jamieson, Sarra E.; Miller, Margaret; Milne, Elizabeth; Norris, Murray D.; Scott, Rodney J.; School of Public Health: Public HealthFolate pathway gene polymorphisms, maternal folic acid use and risk of childhood acute lymphoblastic leukemia, Cancer Epidemiology, Biomarkers and Prevention, vol.24, 1, 2015,pp 48-56
2004Mechanisms Of Embryonal Tumor Initiation: Distinct Roles For Mycn Expression And Mycn Amplification.Armati, Patricia; Burkhart, Catherine A.; Haber, Michelle; Hansford, Loen M.; Keating, Joanna M.; Marshall, Glenn M.; Norris, Murray D.; Peaston, Anne E.; Thomas, Wayne D; Weiss, William A.; Medicine Faculty OfficeMechanisms Of Embryonal Tumor Initiation: Distinct Roles For Mycn Expression And Mycn Amplification., National Academy of Sciences. Proceedings, vol.101,(34),2004,pp 12664-12669
2003Microtubule Alterations and Mutations Induced by Desoxyepothilone B - Implications for Drug-Target InteractionsIvery, Michael; Cobon, Gary S.; Flemming, Claudia L.; Haber, Michelle; Kavallaris, Maria; Liu, Marjorie; Norris, Murray D.; Verrills, Nicole M.; PharmacyMicrotubule Alterations and Mutations Induced by Desoxyepothilone B - Implications for Drug-Target Interactions, Chemistry & Biology, vol.10,(7),2003,pp 597-607
2014Molecular profiling of childhood cancer: Biomarkers and novel therapiesByrne, Jennifer; Haber, Michelle; Marshall, Glenn; McCowage, Geoffrey; Norris, Murray D.; Saletta, Federica; Wadham, Carol; Ziegler, David; Childrens Hospital Westmead: Paediatrics & Child HealthMolecular profiling of childhood cancer: Biomarkers and novel therapies, BBA Clinical, vol.1, N/A, 2014,pp 59-77
2009Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosolAllen, John; Decollogne, Stephanie; Dilda, Pierre J; Haber, Michelle; Hogg, Philip J.; Norris, Murray D.; Weerakoon, Lakmini; Central Clinical School: Centenary InstituteOptimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol, Journal of Medicinal Chemistry, vol.52, 20,pp 6209-6216
2014Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancerBalleine, Rosemary; deFazio, Anna; Emmanuel, Catherine; Gao, Bo-Fu; Harnett, Paul; Wong, Ka (Mark); Beesley, Jonathan; Bowtell, David D L; Chen, Xiao Qinq; Chenevix-Trench, Georgia; Galletta, Laura; Haber, Michelle; Healey, Sue; Henderson, Michelle; Johnatty, Sharon E.; Norris, Murray D.; Russell, Amanda; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead)Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer, Scientific Reports, vol.4, N/A, 2014,pp 1-9
2012The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitroCooper, Caroline; Halliday, Gary; Scolyer, Richard; Wilmott, James; Bell, Jessica; Cheung, Belamy B.; Cunningham, Anne M.; D'andreti, Carla; Haber, Michelle; Kavallaris, Maria; Kim, Patrick; Koach, J; Leigh, Irene; Malyukova, Alena; Marshall, Glenn M.; Norris, Murray D.; Proby, Charlotte; Sekyere, Eric O.; Sutton, Selina; Tan, Owen; Central Clinical School: Pathology; Central Clinical School: Medicine; Central Clinical School: Pathology; Central Clinical School: SurgeryThe retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro, Journal of Pathology, vol.226, 3, 2012,pp 451-462
2015Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastomaO'Neill, Geraldine; Carter, Daniel; Chester, Louis; Cheung, Belamy B; et al, Various; Haber, Michelle; Koach, Jessica; Liu, Bing; Po’uha, Sela; Shum, Michael S Y; Sutton, Selina; Tan, Owen; Childrens Hospital Westmead: Paediatrics & Child HealthThymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma, Molecular Oncology, vol.9, 7, 2015,pp 1484-1500